For trauma patients with exsanguinating torso hemorrhage, resuscitative endovascular balloon occlusion of the aorta (REBOA) did not reduce mortality, and may have increased 90-day mortality, when ...

BOERNE, Texas, Jan. 7, 2025 /PRNewswire/ -- Prytime Medical, The REBOA Company™, proudly announces the first civilian use of its pREBOA-PRO™ catheter in the European Union, following the device's ...

LONDON, Ontario, June 29, 2021 (GLOBE NEWSWIRE) -- Front Line Medical Technologies, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its COBRA-OS™ (Control of Bleeding ...

A new technique used to control severe bleeding in injured patients has been found to likely increase the risk of death, according to new research from the University of Aberdeen. The world's first ...

U.S. Army Medical Research and Development Command Funds FORCE Study to Evaluate Advanced Hemorrhage Control Technology on the Battlefield - Prytime Medical SAN ANTONIO, Nov. 1, 2024 /PRNewswire/ -- ...

REBOA is a minimally invasive technique used by the trauma, critical care and emergency medicine community to temporarily occlude large vessels using a balloon. Pryor Medical Devices has received U.S.

U.S. Department of Defense awards Prytime Medical grant to study the clinical outcomes of the world's first and only catheter designed for Partial REBOA, pREBOA-PRO™ Prytime Medical Inc, The REBOA ...

A new technique used to control severe bleeding in injured patients has been found to increase the risk of death, according to new research from the University of Aberdeen, in Scotland, which was led ...

SAN ANTONIO, Nov. 1, 2024 /PRNewswire/ -- The U.S. Army Medical Research and Development Command has announced a new study that will assess the efficacy of the new 2+ hour pREBOA-PROTM catheter in ...